The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy
- PMID: 15110310
- DOI: 10.1016/j.brachy.2003.12.001
The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy
Abstract
Purpose: To evaluate the effect of hormonal manipulation on catheter dependency, the resolution of urinary symptomatology, and the need for postbrachytherapy transurethral/transincisional resection (TURP/TUIP).
Methods and materials: Seven hundred sixteen consecutive patients (median follow-up, 29 months) underwent brachytherapy for clinical T1b-T3a (1997 AJCC) prostate cancer from January 1998 through August 2002. Of the evaluated cohort, 400 patients were hormone naïve, 227 received short-course cytoreductive (< or = 6 months) hormonal therapy, and 89 received extended (>6 months) hormonal therapy. An alpha-blocker was initiated prior to implantation and continued at least until the International Prostate Symptom Score (I-PSS) returned to baseline levels. Evaluated parameters included age, T-stage, preimplant I-PSS, ultrasound volume, treatment planning volume, hormonal status, supplemental external beam radiation therapy (XRT), isotope, urethral dose, total implant activity, D90, and V100/150/200. Catheter dependency and the incidence of TURP/TUIP were also evaluated.
Results: Six hundred fifty three patients (91.2%) had the urinary catheter permanently removed on day 0 with 15 patients (2.1%) requiring a catheter beyond 4 days. The I-PSS returned to within 1 point of the antecedent value at a median of 4 months. Sixteen patients (2.2%) underwent postimplant TURP/TUIP. A Cox regression indicated that preimplant I-PSS, supplemental XRT, planning target volume, hormonal therapy, and number of seeds were the strongest predictors for I-PSS resolution. Using all available data, the strongest predictors for I-PSS at 18 months following brachytherapy included variants of I-PSS, isotope, and days of catheter dependency. The maximum I-PSS, planning target volume, and XRT best predicted for prolonged (#10878;4 days) catheter dependency. The need for postimplant TURP/TUIP was most closely associated with days of catheter dependency and the maximum increase in I-PSS. However, when only data available prior to implantation was entered into the model, hormonal therapy predicted for postsurgical intervention.
Conclusions: In this retrospective evaluation, hormonal manipulation did not statistically impact short-term or prolonged urinary catheter dependency or I-PSS at 18 months, but did influence time to I-PSS normalization and the need for postbrachytherapy surgical intervention.
Similar articles
-
The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):136-43. doi: 10.1016/j.ijrobp.2005.06.035. Epub 2005 Sep 28. Int J Radiat Oncol Biol Phys. 2006. PMID: 16198062
-
Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1367-82. doi: 10.1016/j.ijrobp.2004.01.017. Int J Radiat Oncol Biol Phys. 2004. PMID: 15275722
-
Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):981-7. doi: 10.1016/j.ijrobp.2004.12.068. Int J Radiat Oncol Biol Phys. 2005. PMID: 15989998
-
Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.J Urol. 2005 Mar;173(3):808-12. doi: 10.1097/01.ju.0000152698.20487.0e. J Urol. 2005. PMID: 15711274 Review.
-
Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.J Urol. 1998 Oct;160(4):1379-82. J Urol. 1998. PMID: 9751358 Review.
Cited by
-
Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.Radiat Oncol. 2014 Jul 24;9:163. doi: 10.1186/1748-717X-9-163. Radiat Oncol. 2014. PMID: 25056726 Free PMC article.
-
TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy.World J Urol. 2009 Jun;27(3):371-7. doi: 10.1007/s00345-008-0354-0. Epub 2008 Nov 28. World J Urol. 2009. PMID: 19039592
-
Acute urinary morbidity following I-125 prostate brachytherapy.Int J Clin Oncol. 2005 Aug;10(4):262-8. doi: 10.1007/s10147-005-0507-8. Int J Clin Oncol. 2005. PMID: 16136372
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical